Therapeutic Advances in Drug Safety

Papers
(The TQCC of Therapeutic Advances in Drug Safety is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews46
Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination21
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review20
Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance20
The danger of diazoxide in the neonatal intensive care unit18
The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and 17
Anticholinergic burden measures and older people’s falls risk: a systematic prognostic review15
Attitudes of ambulatory care older Nepalese patients towards deprescribing and predictors of their willingness to deprescribe14
Pharmacovigilance: reporting requirements throughout a product’s lifecycle14
Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge13
The patterns and implications of potentially suboptimal medicine regimens among older adults: a narrative review13
Systematic review of immunosuppressant guidelines in the COVID-19 pandemic12
Definition of self-medication: a scoping review11
Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes9
Inappropriate medications and physical function: a systematic review9
Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases9
Self-medication and the ‘infodemic’ during mandatory preventive isolation due to the COVID-19 pandemic8
Impact of deprescribing dual-purpose medications on patient-related outcomes for older adults near end-of-life: a systematic review and meta-analysis8
Renin–angiotensin–aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis8
Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies8
Drug safety of frequently used drugs and substances for self-medication in COVID-198
Patients’ attitudes toward deprescribing and their experiences communicating with clinicians and pharmacists7
Safety surveillance and challenges in accelerated COVID-19 vaccine development7
Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials7
Trends in potentially inappropriate opioid prescribing and associated risk factors among Korean noncancer patients prescribed non-injectable opioid analgesics6
Prevalence and global trends of polypharmacy among people living with HIV: a systematic review and meta-analysis6
Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages5
Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register5
The use of a clinical decision support tool to assess the risk of QT drug–drug interactions in community pharmacies5
Patient harm from cardiovascular medications5
Characteristics of voluntary reporting of adverse drug events related to antipsychotics in Australia: 14-year analysis5
The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis5
0.059494018554688